Navigation Links
Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure
Date:8/27/2010

eneral public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About NovartisNovartis Pharmaceuticals Corporation researches, develops, manufactures and markets innovative prescription drugs used to treat a number of diseases and conditions, including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease and respiratory. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. In 2009, the Group's continuing operations achieved net sales of USD 44.3 billion, while approximately USD 7.5 billion was invested in R&D activities throug
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014 Valeritas, Inc., ... designed for patients with Type 2 diabetes, announced today ... Chain Excellence Award. The award was presented October 16 ... Columbus, Ohio . ... judged across a variety of metrics specifically targeted at ...
(Date:10/20/2014)...  AnaptysBio, Inc., a leader in the discovery ... appointment of Marco Londei , M.D. as ... preclinical and clinical development of AnaptysBio,s proprietary antibody ... welcome Dr. Londei to AnaptysBio,s executive leadership team," ... Executive Officer of AnaptysBio. "Dr. Londei,s extensive expertise ...
(Date:10/20/2014)... 20, 2014 Lpath, Inc. (NASDAQ: ... lipid-targeted therapeutics, received official notification from the European Patent ... key patent supporting its iSONEP™ and ASONEP™ programs. ... patent No. 2087002, claims compositions of matter related ... lead compounds, iSONEP and ASONEP. Sonepcizumab is an ...
Breaking Medicine Technology:Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4
... Inc. (NYSE AMEX: ULU), a specialty pharmaceutical ... management and oral care products, today announced it has completed ... Company,s Chairman, President, and Chief Executive Officer. The Company intends ... The convertible notes will bear interest at the rate of ...
... Information Systems ("SIS"), a leader in perioperative information ... has extended its enterprise agreement with SIS by ... implementation will start at North Shore University Hospital and ... hospitals. (Logo:   http://photos.prnewswire.com/prnh/20080722/SISLOGO ) ...
Cached Medicine Technology:ULURU Inc. Raises $140,000 in Convertible Debt Offering 2North Shore-LIJ Health System Selects SIS Anesthesia 2North Shore-LIJ Health System Selects SIS Anesthesia 3North Shore-LIJ Health System Selects SIS Anesthesia 4
(Date:10/22/2014)... Lexington, Kentucky (PRWEB) October 22, 2014 ... an agreement that will change the current location of ... Road to South Limestone across from the University of ... be a state-of-the-art ambulatory care center, owned and operated ... meet the orthopaedic needs of children and their families ...
(Date:10/22/2014)... During the Western United States’ worst ... dangerously low, Southern Oregon’s water is proving resistant to ... lowest mountain snow pack on record in 2014, remain ... autumn.* That was the observation of journalist-hikers Art Bernstein ... Southern Oregon,” during an interview with water advocate Sharon ...
(Date:10/22/2014)... Although there are only 24 hours in a day, that ... trouble finding time within their busy schedules for exercise and fitness. ... time to get in shape. Here are five ways you can ... , Change Up Your Commute , Consider riding a bike or ... into your daily routine. If you must use your car to ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... and length may be showing a genetic propensity for obesity ... genes have been linked to increased body fat, but the ... lean muscle, the researchers said. At 1 year, kids ... 2 and 3, however, these genes were linked to excessive ...
(Date:10/22/2014)... By Maureen Salamon ... -- A crucial part of conventional in vitro fertilization (IVF) ... can instead take place in a device inside the vagina, ... Colombia contend that the device, called an INVOcell, might sharply ... could also make the technology more accessible to those who ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... BEIJING, Aug. 31 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE ... in China, announced,today that Sinovac,s H1N1 vaccine has passed the ... The vaccine is expected to,obtain the production license within this ... 31, 2009, State Food and Drug Administration (SFDA),organized and held ...
... Calif., Aug. 31 Medical costs this year are hitting almost ... a workable solution, Americans face dark days ahead as monthly insurance ... any hope for hard-working Americans who face the challenge of paying ... Americans healthier is by far the most cost effective method of ...
... , , , ... PPHM ), today announced that noted cancer researcher Bruce Chabner, M.D., will ... clinical trials for the bavituximab cancer program. Dr. Chabner is currently ... hematology and oncology at MGH and a professor of medicine at Harvard ...
... , , , ... a global leader in dental and aesthetic lasers, today announced ... Studies (LVI) Global, an internationally renowned provider of post-graduate dental ... branch in Brisbane, Australia. Effective November 1, this new partnership ...
... N. DALLAS/PLANO, Texas, Aug. 31 Beauty injectable fillers ... ability to restore years of lost facial volume in moments. ... experiencing injection discomfort or bruising inhibits them from receiving the ... Dr. Jeffrey Adelglass, M.D., F.A.C.S., a cosmetic surgeon ...
... ANN ARBOR, Mich., Aug. 31 Americans have grown ... , A new report -- Thomson Reuters ... to healthcare expenditures increased 12 percent between March and July. , ... of 3,000 households each month from March through July 2009 -- ...
Cached Medicine News:Health News:Sinovac's H1N1 Vaccine Passes Experts Evaluation Organized by SFDA 2Health News:Sinovac's H1N1 Vaccine Passes Experts Evaluation Organized by SFDA 3Health News:New Book on Meditation Offers a Hands-on Solution to Americans' Health Care Crisis 2Health News:Peregrine Pharmaceuticals Adds Noted Oncologist Dr. Bruce Chabner as Clinical Advisor to Support Advancement of Its Clinical Programs 2Health News:Peregrine Pharmaceuticals Adds Noted Oncologist Dr. Bruce Chabner as Clinical Advisor to Support Advancement of Its Clinical Programs 3Health News:Peregrine Pharmaceuticals Adds Noted Oncologist Dr. Bruce Chabner as Clinical Advisor to Support Advancement of Its Clinical Programs 4Health News:HOYA ConBio Announces Educational Alliance with LVI Global Australia 2Health News:Painless, Bruise-free Dermal Filler Injections 2Health News:Thomson Reuters Study Finds Healthcare Consumer Confidence Improved 12 Percent Since March 2
... pipette is ideal for repeated ... Fixed volume FInnpipettes offer the ... other Finnpipette Digital pipettes: ... (1-40ul), Soft-touch tip ejection, Safety ...
... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... "pipette/tip" system ensures utmost accuracy and precision. ...
Inquire...
... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... "pipette/tip" system ensures utmost accuracy and precision. ...
Medicine Products: